We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+17.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.94B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
8.08%
Top 10 Hldgs %
37.79%
Holding
268
New
72
Increased
34
Reduced
55
Closed
76

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.3M
2
SONX
Sonendo, Inc.
SONX
+$7.34M
3
NTRA icon
Natera
NTRA
+$6.8M
4
AZTA icon
Azenta
AZTA
+$6.45M
5
QTRX icon
Quanterix
QTRX
+$5.89M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$22.4M
2
ILMN icon
Illumina
ILMN
+$11.7M
3
AZN icon
AstraZeneca
AZN
+$9.6M
4
OM icon
Outset Medical
OM
+$8.46M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.3M

Sector Composition

Rank Sector Weight
1 Healthcare 27.35%
2 Industrials 0.25%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NYXH
151
Nyxoah
NYXH
$158M
$801K 0.04%
149,131
-72,818
-33% -$413K
CVAC
152
DELISTED
CureVac
CVAC
$774K 0.04%
+128,245
New +$947K
STVN icon
153
Stevanato
STVN
$5.8B
$755K 0.04%
+42,000
New +$697K
NVTA
154
CALL
DELISTED
Invitae Corporation
NVTA
$744K 0.04%
+400,000
New +$977K
MACK
155
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$735K 0.04%
+64,100
New +$528K
AVTR icon
156
Avantor
AVTR
$9.42B
$732K 0.04%
+34,700
New +$718K
VERA icon
157
Vera Therapeutics
VERA
$2.16B
$684K 0.04%
+35,372
New +$641K
ETNB
158
CALL
DELISTED
89bio
ETNB
$649K 0.03%
+51,000
New +$459K
ETNB
159
DELISTED
89bio
ETNB
$637K 0.03%
+50,000
New +$450K
CVAC
160
CALL
DELISTED
CureVac
CVAC
$603K 0.03%
+100,000
New +$739K
MRTX
161
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$566K 0.03%
+12,500
New +$809K
QGEN icon
162
Qiagen
QGEN
$8.88B
$549K 0.03%
10,374
– –
CBIO
163
CALL
Crescent Biopharma
CBIO
$610M
$535K 0.03%
+1,766
New +$260K
SYRE icon
164
Spyre Therapeutics
SYRE
$9.18B
$472K 0.02%
+41,948
New +$754K
MACK
165
CALL
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$461K 0.02%
+40,200
New +$331K
CERE
166
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$442K 0.02%
14,000
-27,136
-66% -$766K
ISEE
167
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$422K 0.02%
19,700
-14,300
-42% -$305K
NGM
168
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$417K 0.02%
83,154
-52,542
-39% -$329K
VSTM icon
169
Verastem
VSTM
$629M
$404K 0.02%
83,689
– –
ROIVW
170
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
$387K 0.02%
199,648
– –
EOLS icon
171
Evolus
EOLS
$536M
$376K 0.02%
+50,000
New +$387K
CNCE
172
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$347K 0.02%
+59,500
New +$313K
NGM
173
CALL
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$303K 0.02%
60,300
– –
STRO icon
174
Sutro Biopharma
STRO
$353M
$254K 0.01%
+3,141
New +$218K
IMGN
175
DELISTED
Immunogen Inc
IMGN
$248K 0.01%
+50,000
New +$271K
5 6
7
8 9

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Pura Vida Investments held 268 positions worth $1.94B, up 12% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments deployed $157M of net new capital in Q4 2022, opening 72 new positions and adding to 34 existing holdings. Its largest new stake was Natera: 165,000 shares worth $6.63M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 35% a quarter earlier, followed by Industrials and Materials.

On the sell side, the largest reduction was United Therapeutics, an estimated $22.4M trimmed.

  • Pura Vida Investments's largest Q4 2022 buy was Natera: 165,000 shares worth $6.63M.
  • Pura Vida Investments added most to Biogen in Q4 2022, an estimated $16.3M increase.
  • Pura Vida Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $22.4M.
  • Pura Vida Investments fully exited Illumina in Q4 2022, selling an estimated $11.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $1.94B portfolio in Q4 2022.
  • Pura Vida Investments opened 72 new positions and closed 76 in Q4 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $1.94B.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.